PetIQ, Inc. (PETQ) Stock Analysis
DELISTED 2024
What happened to PetIQ, Inc. (PETQ) stock?
PetIQ, Inc. (PETQ) no longer trades on public markets. It was delisted in October 2024. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
PetIQ, Inc. (PETQ) trades at $30.98. PetIQ, Inc. is a pet medication and wellness company operating in the United States and internationally. Market cap: $919M, Sector: Healthcare.
Last analyzed: May 10, 2026Analyst Coverage for PETQ: PETQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PETQ against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
PETQ: the 2 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →PetIQ, Inc. (PETQ) Healthcare & Pipeline Overview
PetIQ, Inc. is a pet medication and wellness company that operates in the United States and internationally, providing a diverse range of products and services, including prescription and over-the-counter medications, health and wellness products, and veterinary services through community clinics, serving a broad market through various distribution channels.
What Is the Investment Thesis for PETQ?
PetIQ, Inc. presents an interesting investment case within the pet health market. The company's dual approach, offering both products and services, allows for diversified revenue streams. The expansion of community clinics and wellness centers could drive revenue growth, particularly as pet ownership continues to rise. The company's focus on value-branded products may appeal to cost-conscious consumers, potentially increasing market share. However, the company's relatively low profit margin of 0.2% and high P/E ratio of 423.6 warrant careful consideration. Upcoming expansion of veterinary services and potential partnerships with major retailers could serve as catalysts. Potential risks include increased competition in the pet medication market and fluctuations in consumer spending.
Based on FMP financials and quantitative analysis
PETQ Key Highlights
Market Cap of $919M reflects investor valuation of PetIQ's growth potential in the pet medication and wellness market.
- P/E Ratio of 423.6 suggests that the company's stock is trading at a high premium relative to its earnings.
- Gross Margin of 22.9% indicates the percentage of revenue exceeding the cost of goods sold, reflecting the company's pricing strategy and production costs.
- The company operates through approximately 60,000 points of distribution across veterinarian, retail, and e-commerce channels, indicating a broad market reach.
- The company offers a suite of services at 2,900 community clinics and wellness centers hosted at pet retailers across 42 states, indicating a significant service footprint.
Who Are PETQ's Competitors?
PETQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| IDXX IDEXX Laboratories, Inc. | $545.86 | -2.91% | $43.1B | 92 |
| ZTS Zoetis Inc. | $75.44 | -1.62% | $31.6B | 85 |
| MRK Merck & Co., Inc. | $152.22 | +12.61% | $376B | 75 |
| COLL Collegium Pharmaceutical, Inc. | $27.54 | -4.18% | $893M | 74 |
| PCRX Pacira BioSciences, Inc. | $24.36 | +1.50% | $958M | 85 |
| AMPH Amphastar Pharmaceuticals, Inc. | $21.74 | +1.87% | $959M | 74 |
| SHPHF Sihuan Pharmaceutical Holdings Group Ltd. | $0.12 | +0.00% | $1.09B | 63 |
| CRON Cronos Group Inc. | $3.22 | -2.13% | $1.20B | 62 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PETQ's Key Strengths?
Wide range of pet medications and wellness products.
- Extensive distribution network.
- Growing network of community clinics.
- Value-branded products appeal to cost-conscious consumers.
What Are PETQ's Weaknesses?
Low profit margin.
- High P/E ratio.
- Reliance on third-party branded medications.
- Limited international presence.
What Could Drive PETQ Stock Higher?
Expansion of community clinics and wellness centers to new locations.
- Development and launch of new proprietary value-branded products.
- Strategic partnerships with major retailers to expand distribution network.
What Are the Key Risks for PETQ?
Rich valuation — a P/E of 423.6 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
- Increased competition in the pet medication market.
- Fluctuations in consumer spending on pet care products and services.
- Regulatory changes impacting the pet health industry.
- Supply chain disruptions affecting product availability and costs.
What Are the Growth Opportunities for PETQ?
- Expansion of Veterinary Services: PetIQ has the opportunity to expand its network of community clinics and wellness centers. With 2,900 locations across 42 states, there is room to increase the number of clinics and expand into new geographic markets. This expansion can drive revenue growth by offering accessible and affordable veterinary services, including vaccinations, diagnostic tests, and prescription medications. The market for veterinary services is estimated to be worth billions of dollars annually, and PetIQ can capture a larger share of this market by increasing its service footprint.
- Development of Proprietary Products: PetIQ can invest in the development and marketing of its own proprietary value-branded products. By creating unique and differentiated products, the company can increase its brand recognition and customer loyalty. This can also improve profit margins by reducing reliance on third-party branded medications. The market for pet health and wellness products is constantly evolving, with new products and formulations being introduced regularly. PetIQ can capitalize on this trend by developing innovative products that meet the changing needs of pet owners.
- Strategic Partnerships: PetIQ can pursue strategic partnerships with major retailers to expand its distribution network and reach new customers. By partnering with large retail chains, the company can increase the visibility of its products and services and gain access to a wider customer base. These partnerships can also provide opportunities for co-marketing and cross-promotion. The retail channel is a significant driver of sales for pet medications and wellness products, and PetIQ can leverage partnerships to increase its market share.
- E-commerce Expansion: PetIQ can further develop its e-commerce platform to increase online sales. With the growing trend of online shopping, PetIQ can capitalize on this trend by offering a convenient and user-friendly online shopping experience. This can also allow the company to reach customers in geographic areas where it does not have a physical presence. The e-commerce channel is becoming increasingly important for pet medications and wellness products, and PetIQ can invest in its online capabilities to drive growth.
- International Expansion: PetIQ can explore opportunities for international expansion to diversify its revenue streams and reduce its reliance on the U.S. market. By expanding into new international markets, the company can tap into new customer bases and increase its overall sales. This expansion can be achieved through partnerships, acquisitions, or organic growth. The global pet care market is growing rapidly, and PetIQ can capitalize on this trend by expanding its international presence.
What Are PETQ's Competitive Advantages?
- Value-branded products offer a cost advantage.
- Extensive distribution network across multiple channels.
- Community clinics provide accessible veterinary services.
- Established brand recognition with brands like PetArmor and VetIQ.
What Does PETQ Do?
PetIQ, Inc., founded in 2010 and headquartered in Eagle, Idaho, operates as a pet medication and wellness company both in the United States and internationally. The company functions through two primary segments: Products and Services. The Products segment focuses on Rx pet medications, including treatments for flea and tick control, heartworm prevention, arthritis, thyroid issues, diabetes, pain management, and antibiotics, alongside specialty medications. PetIQ develops and manufactures its own value-branded products and distributes third-party medications. The company also provides OTC medications and supplies, primarily within the flea and tick control and behavior management categories. These products are available in various forms, such as spot-on treatments, chewables, oral tablets, and collars. The Services segment offers a suite of veterinary services at approximately 2,900 community clinics and wellness centers hosted at pet retailers across 42 states. These services include diagnostic tests, vaccinations, prescription medications, microchipping, and wellness checks. PetIQ's products are marketed under brands like PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PetLock, Heart Shield Plus, TruProfen, Betsy Farms, PetAction, Minties, Vera, and Delightibles. The company distributes its products through approximately 60,000 points of distribution across veterinarian, retail, and e-commerce channels.
What Products and Services Does PETQ Offer?
- Develops and manufactures proprietary value-branded pet medications.
- Distributes third-party branded pet medications.
- Offers over-the-counter (OTC) medications and supplies for pets.
- Provides health and wellness products, including dental treats and nutritional supplements.
- Operates community clinics and wellness centers at pet retailers.
- Offers veterinary services such as diagnostic tests, vaccinations, and prescription medications.
- Distributes products through veterinarian, retail, and e-commerce channels.
How Does PETQ Make Money?
- Sells prescription (Rx) pet medications, including flea and tick control and heartworm preventatives.
- Generates revenue from over-the-counter (OTC) medications and supplies.
- Provides veterinary services at community clinics and wellness centers.
- Distributes products through a network of retail, veterinary, and e-commerce channels.
What Industry Does PETQ Operate In?
PetIQ, Inc. operates within the growing pet care industry, which has seen increased demand for pet medications, wellness products, and veterinary services. The market is driven by rising pet ownership and increased spending on pet health. Competition includes established pharmaceutical companies, generic drug manufacturers, and veterinary service providers. PetIQ's strategy of offering value-branded products and accessible veterinary services positions it to capture a segment of the market focused on affordability and convenience. The pet medication market is expected to continue growing, driven by advancements in veterinary medicine and increasing awareness of pet health issues.
Who Are PETQ's Key Customers?
- Pet owners seeking affordable medications and wellness products.
- Pet owners seeking convenient veterinary services.
- Retail partners hosting PetIQ's community clinics.
- Veterinarians who distribute PetIQ's products.
Company Profile
PetIQ, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Eagle, US. The company is led by CEO McCord Christensen. PETQ has traded publicly since 2017.
Financial Health
PetIQ, Inc.'s Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.51 places it in the grey zone, a middle ground that warrants monitoring.
Key Financial Metrics
Return on equity for PetIQ, Inc. stands at 1.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.2%, showing how much profit it generates from its asset base. PETQ trades at a trailing price-to-earnings ratio of 423.56, above the Healthcare sector average of ~23x. Its free cash flow yield is 5.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.27 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.2%, the inverse of the P/E and a quick read on earnings relative to price.
PETQ Valuation & Market Position
With a $919M market cap, PetIQ, Inc. sits in the small-cap segment of the market.
Forward Outlook
Wall Street analysts project PetIQ, Inc. revenue of about $1.31B for fiscal 2026, with EPS near $1.82.
PETQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in PetIQ's future, indicating that key executives believe in the company's growth potential.
- Community sentiment has been increasingly positive, with discussions highlighting the company's innovative pet health products appealing to a growing market.
- PetIQ's strategic partnerships with major retailers have expanded its distribution channels, enhancing visibility and accessibility of its products.
- The company's focus on expanding its product line aligns well with the increasing demand for premium pet care solutions.
Bear Case
- Concerns over supply chain disruptions have surfaced, potentially impacting product availability and sales in the near term.
- Some community members express skepticism about the sustainability of recent growth trends, questioning whether they can be maintained long-term.
- Increased competition in the pet care market raises concerns about PetIQ's ability to maintain market share and pricing power.
- Recent earnings reports have shown mixed results, leading to caution among investors regarding the company's financial health moving forward.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PETQ Latest News
No recent news available for PETQ.
Leadership: McCord Christensen
CEO
McCord Christensen serves as the CEO of PetIQ, Inc. His background includes extensive experience in the retail and consumer products industries. Prior to joining PetIQ, Christensen held leadership positions at various companies, focusing on strategy, operations, and business development. His expertise spans across multiple functional areas, including sales, marketing, and supply chain management. He brings a wealth of knowledge in driving growth and improving operational efficiency.
Track Record: Under McCord Christensen's leadership, PetIQ, Inc. has focused on expanding its network of community clinics and wellness centers and developing its portfolio of value-branded products. Key milestones include increasing the number of clinic locations and expanding distribution channels. The company has also focused on improving its supply chain and operational efficiency. His strategic decisions have aimed at driving revenue growth and increasing market share.
PETQ Healthcare Stock FAQ
What happened to PetIQ, Inc. (PETQ) stock?
PetIQ, Inc. (PETQ) no longer trades on public markets. It was delisted in October 2024. The figures below are historical and are not a current quote.
Can I still buy PETQ shares?
No. PETQ stopped trading on public markets in October 2024, so the shares are not available through a broker. Anything you see quoted for PETQ elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before PETQ stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to PetIQ, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does PetIQ, Inc. do?
PetIQ, Inc. operates as a pet medication and wellness company, focusing on both product manufacturing and service provision. The company develops, manufactures, and distributes a range of pet medications, including prescription and over-the-counter treatments, as well as health and wellness products. Additionally, PetIQ offers veterinary services through a network of community clinics and wellness centers hosted at pet retailers.
What do analysts say about PETQ stock?
Analyst coverage of PetIQ, Inc. (PETQ) generally focuses on the company's growth potential within the pet health market. Key valuation metrics include the company's P/E ratio and market capitalization. Growth considerations often revolve around the expansion of the company's clinic network, the development of proprietary products, and strategic partnerships.
What are the main risks for PETQ?
PetIQ, Inc. faces several risks inherent to the pet health industry. Increased competition from established pharmaceutical companies and generic drug manufacturers could put pressure on pricing and market share. Fluctuations in consumer spending, particularly during economic downturns, could impact sales of pet medications and wellness products.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Financial metrics are as of the latest available reporting period.